Alcon (Huenenberg, Switzerland) reported FDA approval of its +3.0 diopter that adds power AcrySof IQ ReSTOR intraocular lens. This new lens is now approved in the U.S. for cataract surgery in patients with presbyopia. This lens is another technology advancement for the AcrySof IQ ReSTOR platform, which, according to the company, has been the No. 1 choice of surgeons to correct presbyopia in cataract patients since it was introduced in 2005. The U.S. clinical trials included a three-month follow-up exam of near, intermediate and distance visual acuities. The percentage of patients who achieved 20/20 vision or better at all three distances with the AcrySof IQ ReSTOR +3.0 D was nearly fourfold the rate of patients who received the control lens, AcrySof IQ ReSTOR +4.0 D. The clinical studies also showed a high rate of patient satisfaction with over 95% of patients stating that they would have this lens implanted again, Alcon noted.

Masimo (Irvine, California) reported that noninvasive carboxyhemoglobin (SpCO) and methemoglobin (SpMet) will have CPT coding and pricing under the 2009 Medicare Clinical Laboratory Fee Schedule, effective Jan. 1. The new codes will allow healthcare providers to bill and receive up to $7.33 a day when testing eligible patients, the company said. Masimo develops monitoring technologies designed to improve patient care.